Moderna cuts sales forecast on weaker vaccine demand

Published On Jan 13, 2025, 11:25 AM

Moderna has reduced its sales forecast for 2025 by $1 billion, now expecting between $1.5 billion and $2 billion in revenue. The downgrade is attributed to weak demand for both its COVID-19 vaccine and its recently launched RSV vaccine, which has seen slower uptake. As a result, Moderna's stock dropped more than 20% in early trading. The company's CEO emphasized ongoing cost-cutting strategies, planning to cut cash operating costs by over $1 billion by 2026, and noted overall vaccine demand is declining.

Read full article

Stock Forecasts

AI prediction results, not representative of any investment advice.

MRNA

Negative

With the reduced sales forecast and declining demand for key vaccine products, Moderna's financial outlook appears grim. Analysts anticipate continued pressure on the stock price, influenced by the market's negative reaction and broader concerns about its growth trajectory in the biotech sector.

View MRNA on Yahoo Finance ↗